Application of Cardiogenic Shock Working Group-defined Society for Cardiovascular Angiography and Interventions (CSWG-SCAI) Staging of Cardiogenic Shock to the Medical Information Mart for Intensive Care IV (MIMIC-IV) database

被引:3
|
作者
John, Kevin John [1 ]
Stone, Samuel M. [2 ]
Zhang, Yijing [2 ]
Li, Borui [2 ]
Li, Song [3 ]
Hernandez-Montfort, Jaime [4 ]
Kanwar, Manreet K. [5 ]
Garan, A. Reshad [6 ]
Burkhoff, Daniel [7 ]
Sinha, Shashank S. [8 ]
Sangal, Paavni [2 ]
Harwani, Neil M. [2 ]
Walec, Karol [2 ]
Zazzali, Peter [2 ]
Kapur, Navin K. [2 ,9 ]
机构
[1] Tufts Med Ctr, Dept Med, Boston, MA USA
[2] Tufts Med Ctr, CardioVasc Ctr, Boston, MA USA
[3] Univ Washington, Med Ctr, Seattle, WA USA
[4] Baylor Scott & White Hlth, Adv Heart Failure Program, Temple, TX USA
[5] Cardiovasc Inst Allegheny Hlth Network, Pittsburgh, PA USA
[6] Beth Israel Deaconess Med Ctr, Boston, MA USA
[7] Cardiovasc Res Fdn, New York, NY USA
[8] Inova Heart & Vasc Inst, Falls Church, VA USA
[9] Tufts Med Ctr, 800 Washington St,Box 80, Boston, MA 02111 USA
基金
美国国家卫生研究院;
关键词
Cardiogenic shock; MIMIC-IV; Cardiogenic Shock Working Group; Society for Cardiovascular Angiography and Interventions; SUPPORT;
D O I
10.1016/j.carrev.2023.06.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The optimal parameters for defining stages of cardiogenic shock (CS) are not yet known. The Cardiogenic Shock Working Group-defined Society for Cardiovascular Angiography and Interventions (CSWG-SCAI) staging of CS was developed to provide simple and specific parameters for risk-stratifying patients.Objectives: The purpose of this study was to test whether the Cardiogenic Shock Working Group-defined Society for Cardiovascular Angiography and Interventions (CSWG-SCAI) staging is associated with in-hospital mortality, using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database.Methods: We utilized the open-access MIMIC-IV database, which includes >300,000 patients admitted between 2008 and 2019. We extracted the clinical profile of patients admitted with CS and stratified them into different SCAI stages at admission based on the CSWG criteria. We then tested the association between in-hospital mortality and parameters of hypotension, hypoperfusion, and overall CSWG-SCAI stage.Results: Of the 2463 patients, CS was predominantly caused by heart failure (HF; 54.7 %) or myocardial infarction (MI; 26.3 %). Mortality was 37.5 % for the total cohort, 32.7 % for patients with HF, and 40 % for patients with MI (p < 0.001). Mortality was higher among patients with mean arterial pressure < 65 mmHg, lactate >2 mmol/L, ALT >200 IU/L, pH <= 7.2, and more than one drug/device support at baseline. Increasing CSWG-SCAI stages at baseline and maximum CSWG-SCAI stage achieved were significantly associated with in-hospital mortality (p < 0.05).Conclusions: The CSWG-SCAI stages are significantly associated with in-hospital mortality and may be used to identify hospitalized patients at risk of worsening cardiogenic shock severity.
引用
收藏
页码:82 / 90
页数:9
相关论文
共 2 条
  • [1] Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart for Intensive Care-IV Database
    Haddad, Ghazal
    Maslove, David M.
    Mbuagbaw, Lawrence
    Belley-Cote, Emilie P.
    Rochwerg, Bram
    CRITICAL CARE EXPLORATIONS, 2025, 7 (02) : e1210
  • [2] Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    Gorog, Diana A.
    Price, Susanna
    Sibbing, Dirk
    Baumbach, Andreas
    Capodanno, Davide
    Gigante, Bruna
    Halvorsen, Sigrun
    Huber, Kurt
    Lettino, Maddalena
    Leonardi, Sergio
    Morais, Joao
    Rubboli, Andrea
    Siller-Matula, Jolanta M.
    Storey, Robert F.
    Vranckx, Pascal
    Rocca, Bianca
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (02) : 125 - 140